Related Experiment Videos

Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al

Michael H Schiff

Arthritis Care & Research

|June 4, 2014

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.

Annals of the rheumatic diseases·2018

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.

Rheumatology international·2016

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.

Seminars in arthritis and rheumatism·2015

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.

Annals of the rheumatic diseases·2014

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Annals of the rheumatic diseases·2014

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.

The Journal of rheumatology·2012

See all related articles